It's been a rollercoaster for the CSL (ASX:CSL) share price over the last 6 months

CSL shares have been on the volatility train lately. Here's the details.

| More on:
Scared looking people on a rollercoaster ride representing volatility.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a bumpy ride for CSL Limited (ASX: CSL) shareholders this past 6 months.

For those who can't stomach extreme volatility, CSL shares wouldn't have been an appropriate choice over the last half year.

Nonetheless, CSL shareholders have been rewarded with a 10% return for holding in this time – almost double the S&P/ASX 200 index (ASX: XJO)'s gain of 5.7%.

Let's take a closer look at the trek CSL shares have been on lately.

How has the CSL share price performed this past 6 months?

All in all, CSL shares have climbed $27 per share since April and now trade at $290, after sailing through choppy waters.

After rallying from $263 to $305 in months from April to June, a broker downgrade out of investment bank giant Citibank appears to have plagued the biotechnology company's share price at that point.

It fell sharply from the peak in June to a low of $275 by the following month. It popped again in mid-July after it appointed a new non-executive director, and then again in August after the release of its FY21 results.

In its earnings report, the company outperformed on guidance. It grew revenue 10% year on year to $10 billion and net profit by 10% as well to $2.3 billion – well above guidance of 3% to 8% growth.

CSL shares have been on the move since this event, nearly reaching their 52-week high by the end of September.

However, the CSL share price has taken a step backwards since then, in line with a selloff in the broader markets.

For instance, CSL shares have given away 7% this past month, whereas, at last check, the S&P/ASX 200 Health Care index (XHJ) has also slipped over 6% in this time.

Most of this has occurred in the last few weeks, where CSL shares have slipped over 7% since 23 September, in line with the broad index.

In light of this, it's clear to see that it's been a bumpy ride for CSL shareholders this past 6 months, with big swings in the value of their holdings.

Zooming out the CSL share price

Taking a longer-term view, the situation appears very much the same. The CSL share price has gained 2.4% this year to date, and 1.9% over the last 12 months.

Looking at its chart, however, over this time, there are big swings in price and a wide 12-month range of $316.68 to $246.

After rallying over the past 2 months, CSL's share price has cooled off lately and currently trades at its July 2021 levels of $290.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Healthcare Shares

Why are Mesoblast shares jumping 10% to a 52-week high?

This biotech is hitting new highs on Friday. Let's find out why.

Read more »

a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
Healthcare Shares

Ansell shares tumble to a 3-month low. Is this a buying opportunity?

Ansell shares have slid to a 3-month low. Could oversold signals point to a buying opportunity for long-term investors?

Read more »

Female scientist working in a laboratory.
Healthcare Shares

These three biotechs show how the sector can produce huge outsized gains, but are they still good value?

These drug developers' shares are trading near 12-month highs.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence.
Healthcare Shares

This biotech is approaching 20-bagger status within a year and the good news continues to come

This company has just won approval to go ahead with a key clinical trial.

Read more »

An investor sits at a table in front of her laptop with a party hat on her head and a cake next to her symbolising new year's eve but the 4DS Memory share price is plunging so she looks very disappointed and depressed
Healthcare Shares

$5 billion ASX 200 healthcare stock tumbling on CEO exit

Investors are bidding down the ASX 200 healthcare giant on Thursday. Let’s see why.

Read more »

woman testing substance in laboratory dish, csl share price
Share Market News

After a 73% surge this ASX healthcare share looks far from done

Brokers are upbeat, and some see possible gains of 90% in 2026.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which biotech's shares are surging higher on US patent news?

Investors like what they see from this drug company.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This biotech company's shares are on a tear – again – after another contract win

A new contract with a prestigious US institution spells good news for shareholders.

Read more »